Boston Scientific buys Embolic Protection for $75 million
This article was originally published in Clinica
A week after spending $345 million to buy balloon catheter company Interventional Technologies, Boston Scientific has joined the list of large companies snapping up embolic protection devices. Boston is paying $75 million in cash for Campbell, Georgia-based Embolic Protection (EPI). Boston will also make undisclosed milestone payments.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.